STOCK TITAN

Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Insmed Incorporated (NASDAQ: INSM), a global biopharmaceutical company, has announced its participation in the 2025 Goldman Sachs Annual Global Healthcare Conference. The company's management will deliver a presentation on Wednesday, June 11, 2025, at 9:20 a.m. ET in Miami. Investors and interested parties can access the live webcast through Insmed's investor relations website section at www.insmed.com. The webcast recording will remain available for 30 days after the event concludes.

Insmed Incorporated (NASDAQ: INSM), un'azienda biofarmaceutica globale, ha annunciato la sua partecipazione alla Goldman Sachs Annual Global Healthcare Conference 2025. Il management della società terrà una presentazione il mercoledì 11 giugno 2025 alle 9:20 ET a Miami. Investitori e soggetti interessati potranno seguire la diretta streaming tramite la sezione relazioni con gli investitori del sito www.insmed.com. La registrazione della diretta sarà disponibile per 30 giorni dopo la conclusione dell'evento.

Insmed Incorporated (NASDAQ: INSM), una compañía biofarmacéutica global, ha anunciado su participación en la Conferencia Global Anual de Salud de Goldman Sachs 2025. La dirección de la empresa realizará una presentación el miércoles 11 de junio de 2025 a las 9:20 a.m. ET en Miami. Inversionistas y partes interesadas podrán acceder a la transmisión en vivo a través de la sección de relaciones con inversionistas en www.insmed.com. La grabación estará disponible durante 30 días después de finalizado el evento.

Insmed Incorporated (NASDAQ: INSM)는 글로벌 바이오제약 회사로서 2025년 골드만삭스 연례 글로벌 헬스케어 컨퍼런스에 참여할 것임을 발표했습니다. 회사 경영진은 2025년 6월 11일 수요일 오전 9시 20분(동부시간) 마이애미에서 발표를 진행할 예정입니다. 투자자 및 관심 있는 분들은 Insmed의 투자자 관계 웹사이트(www.insmed.com)를 통해 생중계에 접속할 수 있습니다. 생중계 녹화본은 행사 종료 후 30일간 제공됩니다.

Insmed Incorporated (NASDAQ : INSM), une entreprise biopharmaceutique mondiale, a annoncé sa participation à la Conférence mondiale annuelle sur la santé de Goldman Sachs 2025. La direction de la société présentera le mercredi 11 juin 2025 à 9h20 ET à Miami. Les investisseurs et autres parties intéressées pourront accéder à la diffusion en direct via la section relations investisseurs du site www.insmed.com. L'enregistrement de la diffusion sera disponible pendant 30 jours après la fin de l'événement.

Insmed Incorporated (NASDAQ: INSM), ein globales biopharmazeutisches Unternehmen, hat seine Teilnahme an der Goldman Sachs Annual Global Healthcare Conference 2025 angekündigt. Das Management des Unternehmens wird am Mittwoch, den 11. Juni 2025, um 9:20 Uhr ET in Miami eine Präsentation halten. Investoren und Interessierte können den Live-Webcast über den Bereich Investor Relations auf www.insmed.com verfolgen. Die Aufzeichnung des Webcasts wird 30 Tage nach der Veranstaltung verfügbar sein.

Positive
  • None.
Negative
  • None.

BRIDGEWATER, N.J., May 28, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the 2025 Goldman Sachs Annual Global Healthcare Conference in Miami on Wednesday, June 11, 2025, at 9:20 a.m. ET.

This event will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. Webcasts will be archived for a period of 30 days following the conclusion of the live events.

About Insmed

Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.

Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending four consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more.

Contact:

Investors:

Bryan Dunn
Vice President, Investor Relations
(646) 812-4030
investor.relations@insmed.com

Media:

Claire Mulhearn
Vice President, Corporate Communications
(862) 842-6819
media@insmed.com

Insmed-Logo-Purple (PRNewsfoto/Insmed Incorporated)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-present-at-the-2025-goldman-sachs-annual-global-healthcare-conference-302467030.html

SOURCE Insmed Incorporated

FAQ

When is Insmed (INSM) presenting at the Goldman Sachs Healthcare Conference 2025?

Insmed will present at the Goldman Sachs Healthcare Conference on Wednesday, June 11, 2025, at 9:20 a.m. ET in Miami.

How can I watch Insmed's (INSM) presentation at the Goldman Sachs Healthcare Conference?

The presentation can be accessed through the live webcast on Insmed's investor relations website section at www.insmed.com.

How long will Insmed's (INSM) Goldman Sachs Conference presentation be available to watch?

The webcast will be archived and available for 30 days following the conclusion of the live event.

Where is the 2025 Goldman Sachs Annual Global Healthcare Conference being held?

The 2025 Goldman Sachs Annual Global Healthcare Conference is being held in Miami.
Insmed Inc

NASDAQ:INSM

INSM Rankings

INSM Latest News

INSM Stock Data

12.02B
179.57M
0.98%
112.55%
8.07%
Biotechnology
Pharmaceutical Preparations
Link
United States
BRIDGEWATER